Table 3.
Symptom severity, HR-QOL, uterine and dominant fibroid volumes–ns-PVA versus Embozenes
| ns-PVA (SD, 95% CI) |
Embozene (SD, 95% CI) |
P value | |
|---|---|---|---|
| Symptom Change (n = 63)* | n = 33 | n = 30 | |
| Mean symptom severity score | |||
| a. Pre-UAE | 55.9 | 58.1 | |
| b. Post UAE | 26.6 | 32.8 | |
| Mean change in symptom severity score |
29.2 (26.6, 95% CI 19.8–38.6) |
25.3 (22.8, 95% CI 16.8–33.9) |
0.67 |
| Mean HR quality of life (HR-QOL) | |||
| a. Pre-UAE | 39.1 | 42.9 | |
| b. Post UAE | 76.2 | 70.4 | |
| Mean change in HR quality of life (HR-QOL) | 37.2 | 27.5 | 0.21 |
| Follow-up imaging findings (n = 75)** | n = 41 | n = 34 | |
| Mean uterine volume (cm3) | |||
| a. Pre-UAE | 10,463 | 9523 | |
| b. Post UAE | 6125 | 6477 | |
| Mean change in uterine volume (%) | 42 | 32 | 0.17 |
| Mean dominant fibroid volume (cm3) | |||
| a. Pre-UAE | 3045 | 2466 | |
| b. Post UAE | 1548 | 1500 | |
| Mean change in dominant fibroid volume (%) | 50 | 39 | 0.56 |
Mann–Whitney U test
*63/84 patients completed both their pre- and post UAE symptom scores. **75/84 patients had pre- and post UAE MRI available for review